|
Pilot study of [18F] fluorodexoyglucose positron emission tomography-magnetic resonance imaging (FDG-PET-MRI) for staging of muscle-invasive bladder cancer. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Siemens Healthineers |
Travel, Accommodations, Expenses - Siemens Healthineers |
|
|
No Relationships to Disclose |
|
|
Honoraria - Wake Radiology |
Consulting or Advisory Role - Lucerno Dynamics; Philips Healthcare |
Travel, Accommodations, Expenses - Philips Healthcare |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb; GeneCentric; Roche/Genentech; X4 Pharma |
|
|
Stock and Other Ownership Interests - MDxHealth |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck; Photocure |
|
|
Stock and Other Ownership Interests - Grand Rounds Health |
|
|
Research Funding - Astellas Pharma (Inst); Clovis Oncology (Inst); Innocrin Pharma (Inst) |
|
|
Stock and Other Ownership Interests - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb; FibroGen; G1 Therapeutics; Illumina; Johnson & Johnson; Kura Oncology; Spectrum Pharmaceuticals |
|
Consulting or Advisory Role - Foundation Medicine; GeneCentric |
Research Funding - Foundation Medicine; GeneCentric; Merck |
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier |
Travel, Accommodations, Expenses - Takeda |
|
|
Consulting or Advisory Role - Merck (I) |
Expert Testimony - Wockhardt Pharmaceuticals |
|
|
Consulting or Advisory Role - Carevive Systems; Selecta Biosciences; SIVAN Innovation |
Other Relationship - American Society of Clinical Oncology; Centers for Medicare and Medicaid Services; JAMA-Journal of the American Medical Association; National Cancer Institute |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BioClin Therapeutics |
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); X4 Pharma (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
Other Relationship - Asieris Pharmaceuticals |